Exodus Point Capital Management, LP I Teos Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$10.33 - $18.09 $222,270 - $389,242	21,517 Added 133.18%	37,673 $559,000
Q1 2024 May 14, 2024	SELL	$9.89 - $13.64 $57,747 - $79,643	-5,839 Reduced 26.55%	16,156 $220,000
Q3 2023 Nov 09, 2023	BUY	$10.95 - $14.6 $72,018 - $96,024	6,577 Added 42.66%	21,995 $241,000
Q2 2023 Aug 10, 2023	BUY	$12.93 - $18.05 $199,354 - $278,294	15,418 New	15,418 $204,000
Q2 2022 Aug 19, 2022	SELL	$16.57 - $35.1 $419,635 - $888,907	-25,325 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$31.92 - $47.45 $1.79 Million - $2.67 Million	-56,186 Reduced 68.93%	25,325 $815,000
Q4 2021 Feb 11, 2022	BUY	$26.23 - $47.86 $2.14 Million - $3.9 Million	81,511 New	81,511 $3.8 Million

165

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $293M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.